Patti, Iran

Celyad Oncology Reports First Half 2021 Financial Results and Recent Business Highlights

Retrieved on: 
Wednesday, August 4, 2021

This is an exciting time in our Companys history as we plan for a steady stream of milestones in the second half of 2021, commented Filippo Petti, Chief Executive Officer of Celyad Oncology.

Key Points: 
  • This is an exciting time in our Companys history as we plan for a steady stream of milestones in the second half of 2021, commented Filippo Petti, Chief Executive Officer of Celyad Oncology.
  • Research & Development Day held on July 20, 2021, during which the management team provided:
    Updates on the allogeneic CAR T clinical candidates CYAD-211 and CYAD-101.
  • Report additional data from the dose-escalation Phase 1 CYCLE-1 trial evaluating CYAD-02 in r/r AML and MDS by year-end 2021.
  • Key financial figures for the first half of 2021, compared with the first half of 2020 and full year 2020, are summarized below: